Login / Signup

Nano-CeO 2 -Loaded Polyzwitterionic Double-Network High-Strength Hydrogel for Highly Enhanced Synergistic Marine Antifouling.

Yangkai XiongZhiqiang FangDaxiong HuHao JiangLei HuangQitong MaoGuoqing WangJipeng LiZhenzhong LiuChunxin Ma
Published in: ACS applied materials & interfaces (2023)
Although many antibiofouling materials have been developed based on either bacterial-killing or antiadhesion effects, the integration of both the effects in one material remains challenging for achieving highly enhanced synergistic antibiofouling. In this study, we have explored a nano-CeO 2 -loaded double-network hydrogel by introducing CeO 2 nanorods into a polyzwitterionic hydrogel via a simple one-pot method for achieving highly efficient antifouling. First, the CeO 2 nanorods dispersed in the hydrogel, as an outstanding nanozyme, have highly efficient bacterial-killing performance. Second, the superhydrophilic polyzwitterionic hydrogel provides a dense hydrated layer on the surface and subsequently excellent broad-spectrum antiadhesion behavior. Most importantly, the bacterial killing and antiadhesion of this hydrogel can work synergistically to largely improve the marine-antifouling performance. Moreover, the double-network structure of this hydrogel, including the covalently cross-linked polyzwitterion hard network and the physically cross-linked poly(vinyl alcohol) soft network, can provide greatly improved mechanical properties (2.44 MPa of tensile strength reaches and 21.87 MPa of compressive strength). As a result, among the existing marine-antifouling hydrogels, the CeO 2 -loaded polyzwitterionic double-network hydrogel can achieve outstanding antifouling performance, which can sustain for over 6 months in a real marine environment. This work provides a promising marine-antifouling hydrogel, which will also inspire antifouling research of a new strategy and materials.
Keyphrases
  • drug delivery
  • wound healing
  • hyaluronic acid
  • highly efficient
  • cancer therapy
  • tissue engineering
  • drug release